Navigation Links
Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
Date:6/22/2012

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications. Bone marrow failure and conversion to acute leukemia may occur in patients with MDS, necessitating bone marrow transplantation. The disease can be caused by chemotherapy and radiation treatment for cancer.

Deferasirox, the drug tested in the clinical trial, was aimed at reducing the elevated and risky iron levels that accompany the red blood cell transfusions. The study drug was received by 173 patients.

"The majority of patients with MDS require red blood cell transfusions for their anemia, but this leaves them at risk for iron overload," said study co-author Alan F. List, M.D., Moffitt's executive vice president and physician-in-chief. "Organ complications can arise for transfusion-dependent patients with MDS."

The two most serious complications for those with MDS, once called pre-leukemia, are infection and iron overload from transfused red blood cells.

When Robin Roberts, ABC's "Good Morning America" co-anchor, announced on the air in June that she has MDS and would undergo a bone marrow transplant, MDS was brought into sharp focus for Americans. At the time of her announcement, Roberts had been free of breast cancer for five years and had undergone chemotherapy and radiation.

The clinical trial results, published in a recent issue of the Journal of Clinical Oncology, show that deferasirox reduced iron (serum ferritin) by 23 percent in 53 percent of the patients who completed 12 months of treatment, reduced the blood iron in 36.7 percent of patients who had been on the treatment for two years, and patients who had been on the treatment for three years saw a 36.5 percent reduction in serum ferritin.

The drug also reduced labile plasma iron (LPI), called the most toxic aspect of nontransferrin-bound iron that accumulates after the body's iron storage capacity has been saturated.

"Overall, this study demonstrated improvements in iron parameters in a group of heavily transfused lower risk patients with MDS," explained List, whose research focuses on the biology of MDS and potential treatments. "A randomized trial is warranted to better ascertain the clinical impact of deferasirox therapy in lower risk patients with MDS."


'/>"/>
Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Cedars-Sinai physician definitively links irritable bowel syndrome and bacteria in gut
2. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
3. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
4. Pseudo Gout Is Now Being Treated With Regenerative Medicine At The Center For Regenerative Medicine
5. Advanced Osteoarthritis Of The Knee Is Now Being Treated With Regenerative Medicine At The Center For Regenerative Medicine
6. Obesity, A Contributing Cause Of Arthritis Of The Knee, Is Now Being Treated With Regenerative Medicine At The Center For Regenerative Medicine
7. High Rates of Untreated Kidney Failure Seen in Elderly
8. Genu Valgum Of The Knee Is Now Being Treated With Regenerative Medicine At The Center For Regenerative Medicine
9. Many poor pregnant women with HIV go untreated for depression
10. Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo
11. 1 in 5 Americans Has Untreated Cavities: CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... DIEGO, California (PRWEB) , ... June 20, 2017 ... ... product documentation and help content solutions for the enterprise, is proud to announce ... properties, including CRM, e-commerce, ticketing systems, company websites, and more to provide a ...
(Date:6/20/2017)... Cincinnati, Ohio (PRWEB) , ... June 20, 2017 ... ... with gum disease in Cincinnati, OH for leading-edge care, whether or ... advances in laser dentistry. Using the BIOLASE WaterLase® iPlus™ laser, she targets bacteria ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience ... in Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at ... traditional orthodontics can cause for some patients, which is why they offer the latest ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants ... focused on finding product improvements that could reduce the occurrence of unplanned extubations ... need help breathing or to provide medication. Sometimes, patient movement can cause unplanned ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished ... Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other businesses from ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... June 12, 2017 Kineta, Inc., a biotechnology company ... Kineta Vice President of R&D and Head of Virology ... Pandemic Preparedness for the Northwest and Beyond meeting sponsored ... June 14, 2017 from 8:30-10:30 AM PDT at the Agora ... Dr. Bedard will be joined by other leaders ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
Breaking Medicine Technology: